The European Commission has approved on Nov. 10 a deal with French vaccine company Valneva to supply up to 60 million doses of its COVID-19 vaccine candidate over the next two years.
Under the deal, nearly 27 million doses of the vaccine is currently expected to arrive in April 2022.
The deal also allows European Union member states to make a further order of up to 33 million additional vaccines in 2023.
The contract also allows for the vaccine to be adapted to new variants.
The vaccine is still subject to approval by the European Medicines Agency.
Valneva said they were “grateful” for the deal.
“We are deeply committed to bringing an alternative vaccine solution to the market as quickly as possible and continue to work tirelessly to achieve that,” Valneva Chief Executive Thomas Lingelbach said in a statement.
“Our Phase 3 results confirmed the advantages often associated with inactivated vaccines and we continue to believe that our differentiated vaccine candidate could make an important contribution to the global fight against the COVID-19 pandemic,” Lingelbach further said.
The deal is the European Commission’s eight COVID-19 vaccine contract with a pharmaceutical company, expanding its portfolio that already includes AstraZeneca, Pfizer-BioNTech, and Moderna.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.